A Comprehensive Monograph on D-Glutamine: From Molecular Identity to Emerging Therapeutic Potential

Executive Summary

D-Glutamine, the dextrorotatory enantiomer of the ubiquitous amino acid glutamine, has long been relegated to the periphery of biochemical research, often labeled as an "unnatural" isomer with limited biological significance in mammals. This report provides a comprehensive examination of D-Glutamine (DrugBank ID: DB02174), synthesizing data from chemical databases, metabolic studies, and emerging therapeutic research to construct a nuanced and detailed profile. While its isomer, L-Glutamine, is a cornerstone of mammalian metabolism—serving as a proteinogenic building block, a primary nitrogen shuttle, and a critical fuel for rapidly dividing cells—D-Glutamine follows a starkly different path. It is not incorporated into proteins and does not participate in the canonical glutaminolysis pathway that is vital for many cells, particularly in oncology.

Instead, the biological activity and potential pharmacology of D-Glutamine are almost exclusively dictated by a single enzyme: D-amino acid oxidase (DAAO). This flavoenzyme, primarily located in the kidney, liver, and specific regions of the brain, catalyzes the oxidative deamination of D-Glutamine, producing 2-oxoglutaramate, ammonia, and the reactive oxygen species hydrogen peroxide. This metabolic fate positions D-Glutamine not as a nutrient, but as a potential prodrug whose effects are spatially restricted to tissues expressing DAAO. This mechanism presents a therapeutic paradox: whereas L-Glutamine supplementation is often used for its protective, antioxidant-precursor roles, D-Glutamine administration holds potential for targeted, pro-oxidant cytotoxicity.

Emerging research highlights the potential of D-Glutamine as a disease biomarker, with altered levels observed in hepatocellular carcinoma and colorectal cancer, although the data suggest complex, tissue-specific metabolic dysregulation. While its L-isomer has achieved regulatory approval for conditions like sickle cell disease, D-Glutamine remains a research chemical. However, within the burgeoning field of D-amino acid therapeutics, D-Glutamine represents a compelling area for future investigation. Its unique, DAAO-dependent metabolism suggests a potential for precision medicine applications, particularly in oncology, where it could be used to selectively target DAAO-expressing tumors. This report elucidates the foundational chemistry, comparative metabolism, pharmacology, and toxicology of D-Glutamine, culminating in a forward-looking analysis of its future research trajectory, which may see it transition from a biochemical curiosity to a targeted therapeutic agent.

1.0 Compound Identification and Physicochemical Properties

This section establishes the fundamental chemical and physical identity of D-Glutamine, providing a consolidated reference from multiple authoritative databases to ensure an unambiguous foundation for subsequent biological and pharmacological discussion.

1.1 Nomenclature and Chemical Identifiers

D-Glutamine is recognized by a variety of names and unique identifiers across chemical and biological databases, which are essential for accurate literature retrieval and cross-referencing.

• Generic Name: D-Glutamine.[1]
• Systematic (IUPAC) Name: The chemically precise name is (2R)-2,5-diamino-5-oxopentanoic acid. The "(2R)" designation specifies the absolute stereochemistry at the alpha-carbon, which is the defining feature that distinguishes it from its L-enantiomer.[1]
• Synonyms: A comprehensive list of synonyms includes D-Gln, D-Gln-OH, (R)-2-Amino-4-carbamoyl-butyric acid, D-2-Aminoglutaramic acid, D-Glutamin, and D-Glutaminsäure-5-amid.[1]
• Key Identifiers: The consistency of identifiers across major international databases confirms a well-defined and universally recognized chemical entity. The most critical identifiers are those that encode its specific stereochemistry, preventing confusion with L-Glutamine.

Identifier Type	Value	Source(s)
DrugBank ID	DB02174	1
CAS Number	5959-95-5	2
PubChem CID	145815	2
ChEBI ID	CHEBI:17061	2
HMDB ID	HMDB0003423	2
KEGG ID	C00819	2
UNII	63HB36CA2Y	2

1.2 Molecular Structure and Stereochemistry

The molecular structure and stereochemistry of D-Glutamine are fundamental to its distinct biological properties.

• Molecular Formula: C5​H10​N2​O3​.[2]
• Molecular Weight: Values of 146.14 g/mol and 146.15 g/mol are reported, with the minor difference attributable to isotopic mass calculations.[2] The monoisotopic mass is 146.069142196 Da.[2]
• Canonical SMILES: The Simplified Molecular Input Line Entry System (SMILES) string is C(CC(=O)N)[C@H](C(=O)O)N.[2] The [C@H] notation is a critical element, explicitly defining the R-configuration (dextrorotatory) at the chiral alpha-carbon center.
• InChIKey: The International Chemical Identifier Key is ZDXPYRJPNDTMRX-GSVOUGTGSA-N.[2] This hashed identifier is unique to D-Glutamine and encodes its specific constitution, connectivity, and stereochemistry, unambiguously distinguishing it from L-Glutamine, which has a different InChIKey.
• Classification: D-Glutamine is classified as a D-alpha-amino acid. It belongs to the broader chemical ontology of amino acids, peptides, and proteins and is the direct enantiomer of L-Glutamine.[1]

1.3 Physicochemical and Spectrometric Data

The physical and chemical properties of D-Glutamine govern its behavior in solution and its potential interactions within biological systems.

• Physical Appearance: D-Glutamine is described as a white crystalline powder under standard conditions.[3]
• Solubility: It exhibits high solubility in aqueous solutions, with a reported water solubility of 97.8 mg/mL.[1] It is also noted as being partially soluble in ethanol and soluble in phosphate-buffered saline (PBS, pH 7.2) at a concentration of 10 mg/ml.[4]
• Predicted Physicochemical Properties: Computational models provide valuable predictions of the molecule's behavior. Key predicted properties are summarized below [1]:
• logP (Octanol-Water Partition Coefficient): Values range from -3.3 to -4, indicating that D-Glutamine is highly hydrophilic and partitions preferentially into aqueous environments over lipid environments.
• pKa: The strongest acidic pKa is predicted to be 2.15 (corresponding to the carboxyl group), and the strongest basic pKa is 9.31 (corresponding to the alpha-amino group). At physiological pH (~7.4), the molecule exists predominantly as a zwitterion with a net physiological charge of 0.
• Polar Surface Area (PSA): 106.41 A˚2. This large PSA, combined with 3 hydrogen bond donors and 4 hydrogen bond acceptors, further confirms its polar and hydrophilic nature.
• Drug-likeness Rules: D-Glutamine complies with Lipinski's Rule of Five, suggesting it possesses physicochemical properties generally associated with orally active drugs. However, it fails Ghose, Veber's, and MDDR-like filters, which are more stringent criteria often applied in drug discovery screening.[1]
• Predicted Bioavailability: Computational models predict a high bioavailability of 1, suggesting efficient absorption is likely.[1]
• Spectrometric Data: Experimental mass spectrometry data for D-Glutamine is publicly available, providing an empirical fingerprint for its identification. A tandem mass spectrometry (MS/MS) spectrum, acquired on a Quattro_QQQ instrument with a collision energy of 25V in positive ionization mode, is cataloged in DrugBank under its accession number, DB02174.[8] This data is crucial for the unambiguous identification of D-Glutamine in metabolomic and pharmacokinetic studies.

2.0 The Glutamine Enantiomers: A Comparative Biological and Metabolic Overview

To comprehend the unique characteristics of D-Glutamine, it is essential to first understand the well-established and dominant role of its stereoisomer, L-Glutamine. The profound differences in their biological abundance, metabolic fate, and physiological function form the central theme of this report and explain why D-Glutamine, while structurally similar, operates in a distinct biochemical niche.

2.1 L-Glutamine: The Biologically Dominant and Conditionally Essential Isomer

L-Glutamine is the most abundant free amino acid in human plasma and tissues, particularly skeletal muscle, which accounts for approximately 90% of its synthesis.[9] Synthesized from glutamate and ammonia by the enzyme glutamine synthetase, L-Glutamine is a cornerstone of mammalian physiology with a multitude of roles [10]:

• Protein Synthesis: As one of the 20 proteinogenic amino acids, it is a fundamental building block for the synthesis of proteins, encoded by the codons CAA and CAG.[10]
• Metabolic Fuel: It is a primary energy source for rapidly proliferating cells, including enterocytes of the gut mucosa, lymphocytes, and macrophages. The rate of glutamine consumption by these immune cells can be similar to or greater than that of glucose.[9]
• Nitrogen Transport: With two nitrogen moieties, it serves as the principal non-toxic transporter of ammonia in the blood, shuttling nitrogen between organs for various anabolic processes.[1]
• Biosynthetic Precursor: L-Glutamine is a critical precursor for the synthesis of other molecules, including other non-essential amino acids, purine and pyrimidine nucleotides (for DNA and RNA synthesis), and amino sugars.[10]
• Neurotransmission and Redox Balance: It can cross the blood-brain barrier and is a key precursor for the synthesis of the primary excitatory neurotransmitter, glutamate, and the inhibitory neurotransmitter, GABA.[10] It is also a component of glutathione (GSH), the body's most important endogenous antioxidant, thereby playing a vital role in maintaining cellular redox homeostasis.[16]

Under normal physiological conditions, the body can synthesize sufficient L-Glutamine, classifying it as a non-essential amino acid. However, during periods of severe metabolic stress—such as critical illness, major surgery, trauma, or sepsis—the body's demand for L-Glutamine can exceed its synthetic capacity. In these states, it becomes a conditionally essential amino acid, requiring supplementation to support immune function, maintain gut integrity, and meet metabolic demands.[10]

2.2 D-Glutamine: The "Unnatural" Isomer and Its Niche Existence

In stark contrast to its L-isomer, D-Glutamine is often described as the "unnatural isomer" and is considered "relatively unimportant in living organisms" from the perspective of mainstream metabolic pathways.[19] It is not used for protein synthesis in humans and is not found in significant quantities in dietary sources, which are rich in L-Glutamine.[20]

While D-amino acids are generally rare in mammals, they are not entirely absent. They are essential components of the peptidoglycan cell walls of bacteria, and thus the gut microbiome represents an exogenous source.[23] Furthermore, trace amounts of certain D-amino acids, including D-Glutamine, are endogenously present in mammalian tissues, such as the brain, where they may have specific, albeit not fully understood, signaling or metabolic roles.[25]

2.3 Comparative Metabolism: A Fundamental Divergence

The most profound distinction between the two enantiomers lies in their metabolic fate. This divergence is not merely a subtle difference but a fundamental split that dictates their entirely separate physiological consequences.

• L-Glutamine Metabolism (Glutaminolysis): The primary catabolic pathway for L-Glutamine is known as glutaminolysis. This process begins with the mitochondrial enzyme glutaminase (GLS), which hydrolyzes L-Glutamine to L-glutamate and ammonia. L-glutamate is then converted by glutamate dehydrogenase or transaminases into α-ketoglutarate (α-KG), a key intermediate that enters the tricarboxylic acid (TCA) cycle. This pathway is crucial for generating ATP, replenishing TCA cycle intermediates (anaplerosis), and providing precursors for biosynthesis. This pathway is particularly hyperactive in many cancer cells, a phenomenon termed "glutamine addiction".[13]
• D-Glutamine Metabolism (Oxidative Deamination): D-Glutamine is not a substrate for glutaminase and therefore does not participate in glutaminolysis. Its primary metabolic pathway in mammals is oxidative deamination, a reaction catalyzed exclusively by the FAD-dependent flavoenzyme D-Amino Acid Oxidase (DAAO).[30] This enzyme stereoselectively acts on D-amino acids, converting D-Glutamine into three distinct products: 2-oxoglutaramate, ammonia (NH4+​), and hydrogen peroxide (H2​O2​).[33]

This metabolic distinction is absolute and forms the basis for the differing pharmacology and toxicology of the two isomers. The following table provides a concise comparison of their key attributes.

Feature	L-Glutamine	D-Glutamine	Key Reference(s)
Stereochemistry	Levorotatory (L-), (2S)-configuration	Dextrorotatory (D-), (2R)-configuration	2
Biological Abundance	Most abundant free amino acid in the body	Trace amounts, considered "unnatural"	10
Primary Role	Protein synthesis, metabolic fuel, nitrogen transport, biosynthetic precursor	Substrate for D-Amino Acid Oxidase (DAAO)	10
Primary Metabolic Pathway	Glutaminolysis	Oxidative Deamination	13
Key Metabolic Enzyme(s)	Glutaminase (GLS), Glutamine Synthetase (GS)	D-Amino Acid Oxidase (DAAO)	10
Key Metabolic Products	L-Glutamate, α-Ketoglutarate	2-Oxoglutaramate, Ammonia (NH4+​), Hydrogen Peroxide (H2​O2​)	13
Regulatory Status	FDA-approved drug (Endari®, NutreStore™)	Research-grade chemical	34

The seemingly minor structural difference—the spatial arrangement around a single carbon atom—results in two molecules with fundamentally different biological roles. L-Glutamine is an integral, pleiotropic component of core metabolism. D-Glutamine, by contrast, is a metabolic outsider. However, its very "unimportance" in conventional pathways is what confers its pharmacological potential. Because its biological activity is not diffuse across countless metabolic networks but is instead narrowly channeled through a single enzyme, DAAO, its effects can be highly specific. This suggests that the biological impact of D-Glutamine is not inherent to the molecule itself but is conditional upon the presence and activity of DAAO in a given tissue. This transforms the perception of D-Glutamine from a simple isomer to a potential prodrug, whose action can be spatially and temporally controlled by the tissue-specific expression of its activating enzyme.

3.0 Pharmacology of D-Glutamine

The pharmacology of D-Glutamine is fundamentally distinct from that of its L-isomer. It does not engage with the vast network of pathways associated with L-Glutamine but instead derives its activity almost exclusively from its interaction with a single, highly specific enzyme system. This section details the pharmacodynamics and inferred pharmacokinetics of D-Glutamine, centered on the pivotal role of D-amino acid oxidase.

3.1 Pharmacodynamics: The Central Role of D-Amino Acid Oxidase (DAAO)

The primary, and to date only known, pharmacodynamic mechanism of D-Glutamine in mammals is to serve as a substrate for the enzyme D-amino acid oxidase (DAAO; EC 1.4.3.3).[30]

• Mechanism of Action: DAAO is a peroxisomal flavoenzyme that contains a flavin adenine dinucleotide (FAD) cofactor. It exhibits absolute stereoselectivity, catalyzing the oxidative deamination of various neutral D-amino acids while being inactive towards their L-enantiomers and acidic D-amino acids.[30] The enzymatic reaction proceeds as follows: D−Glutamine+O2​+H2​ODAAO​2−oxoglutaramate+NH4+​+H2​O2​

This reaction converts the D-amino acid into its corresponding α-keto acid (2-oxoglutaramate), releasing ammonia (NH4+​) and producing hydrogen peroxide (H2​O2​) as a byproduct of the reoxidation of the reduced FAD cofactor by molecular oxygen.32

• Physiological Implications of Metabolites: The products of this reaction have significant biological activities and toxicological potential:
• Hydrogen Peroxide (H2​O2​): As a potent reactive oxygen species (ROS), H2​O2​ can induce oxidative stress, damage cellular components like DNA, lipids, and proteins, and ultimately trigger cell death pathways such as apoptosis.[32] This pro-oxidant effect is the basis for the potential cytotoxicity of D-amino acid/DAAO systems and stands in direct contrast to the role of L-Glutamine as a precursor for the antioxidant glutathione.
• Ammonia (NH4+​): Ammonia is a neurotoxic compound that must be detoxified, primarily by the liver through the urea cycle. Elevated levels of ammonia (hyperammonemia) can lead to severe neurological dysfunction, including hepatic encephalopathy. Therefore, the administration of any substrate that generates ammonia carries a potential risk, especially in individuals with compromised liver function.[12]
• 2-oxoglutaramate: This α-keto acid is the carbon skeleton of D-Glutamine. While its specific metabolic fate is not detailed in the available literature, α-keto acids can potentially be re-aminated to form amino acids or enter other central metabolic pathways.

3.2 Human DAAO (hDAAO) Substrate Specificity and Tissue Distribution

The effect of D-Glutamine administration is critically dependent on the characteristics and location of the hDAAO enzyme.

• Tissue Distribution: DAAO expression is not uniform throughout the body. The highest levels are found in the kidney (proximal tubules) and liver, where its primary function is believed to be the detoxification of D-amino acids from dietary or gut microbial sources.[24] Significant expression is also found in the brain, particularly in astrocytes of the cerebellum and other hindbrain regions, where it plays a key role in regulating the levels of the neuromodulator D-serine.[30] This tissue-specific expression pattern means that the metabolic effects of D-Glutamine will be concentrated in these organs.
• Substrate Profile: hDAAO has a broad substrate specificity but shows a clear preference for neutral, hydrophobic D-amino acids. It is inactive towards acidic D-amino acids such as D-glutamate and D-aspartate.[31] The kinetic efficiency varies greatly among substrates. D-Glutamine is a confirmed substrate, but its specific kinetic parameters (e.g., Km​, kcat​) relative to other D-amino acids are not reported in the provided materials. Understanding this relative efficiency is crucial for predicting its metabolic turnover rate.

To contextualize D-Glutamine's role, the following table summarizes the specificity of hDAAO for various relevant substrates.

D-Amino Acid Substrate	Relative Catalytic Efficiency	Physiological Relevance / Notes	Source(s)
D-Cysteine	Highest reported efficiency (44-fold > D-Serine)	Substrate for H2​S production; potential role in vascular tone and cytoprotection.	36
D-Tyrosine	High	Intermediate in dopamine biosynthesis pathway.	36
D-Phenylalanine	High	Aromatic amino acid.	36
D-DOPA	Highest kcat​ value, but lower efficiency than D-Tyrosine due to high Km​	Precursor for dopamine.	36
D-Serine	Low	Key physiological substrate in the brain; regulates NMDA receptor activity.	30
D-Alanine	Active	Substrate in brain and periphery.	36
D-Glutamine	Confirmed Substrate (Kinetic parameters not reported)	Found endogenously in the brain; potential as a biomarker or therapeutic.	26
D-Aspartate	Negligible activity	Not a significant substrate for hDAAO; metabolized by D-aspartate oxidase (DDO).	36

3.3 Pharmacokinetics (Absorption, Distribution, Metabolism, Excretion - ADME)

Direct experimental pharmacokinetic data for D-Glutamine in humans or animals are not available in the provided research materials.[42] However, an ADME profile can be inferred based on its physicochemical properties and the known behavior of related compounds.

• Absorption: As a small, highly hydrophilic amino acid that complies with the Rule of Five and has a predicted bioavailability of 1, D-Glutamine is expected to be efficiently absorbed from the gastrointestinal tract following oral administration, likely via one or more of the numerous amino acid transport systems.[1]
• Distribution: Following absorption, it would be expected to distribute into the total body water. Its ability to cross the blood-brain barrier is a critical but unanswered question. Its structural analogue, L-Glutamine, is actively transported into the brain, making it plausible that D-Glutamine may also have some capacity to enter the central nervous system.[10]
• Metabolism: As established, metabolism is the primary route of elimination and is exclusively mediated by DAAO. The principal organs of metabolism are therefore the kidneys and the liver, where DAAO is most abundant.[30] Studies using D-leucine in rats with reduced renal mass have definitively shown that the kidney is the principal organ for the metabolic conversion of D-amino acids, underscoring the importance of renal function in D-Glutamine disposition.[43]
• Excretion: Any D-Glutamine that is not metabolized by DAAO would be subject to renal elimination. Like other amino acids, it would be freely filtered by the glomerulus and then almost completely reabsorbed by active transport mechanisms in the renal tubules.[42] The metabolites—2-oxoglutaramate, ammonia (converted to urea), and water (from H2​O2​ reduction)—would be excreted in the urine.

The overall pharmacokinetic profile of D-Glutamine is likely determined by a dynamic interplay between its rate of metabolism by DAAO and its rate of renal clearance. This balance would be highly sensitive to patient-specific factors. For instance, genetic polymorphisms in the DAAO gene could lead to significant inter-individual variability in metabolic capacity. Likewise, patients with chronic kidney disease would experience a dual impairment: a reduction in the mass of DAAO-expressing tissue and a decrease in the glomerular filtration rate. This combination would predictably lead to a substantially prolonged half-life and increased systemic exposure to D-Glutamine, heightening the risk of potential toxicity. These considerations are paramount for any future clinical development and suggest that dosing may need to be personalized based on both renal function and DAAO genotype.

4.0 Toxicology and Safety Profile

The safety assessment of D-Glutamine is complex due to a lack of direct toxicological studies. Its profile must be inferred by contrasting it with the well-documented safety of L-Glutamine and by analyzing the specific toxicological mechanisms of the metabolites generated by its unique DAAO-dependent pathway.

4.1 Safety of L-Glutamine: A Baseline for Comparison

L-Glutamine is generally regarded as safe for human consumption, even at high doses. This established safety profile provides a useful, albeit imperfect, reference point.

• General Tolerance and Side Effects: Oral supplementation with L-Glutamine is typically well-tolerated, with doses up to 40 grams per day considered likely safe for adults.[44] When side effects occur, they are generally mild and gastrointestinal in nature, such as bloating, nausea, constipation, heartburn, and stomach pain.[17]
• Concerns with High-Dose and Long-Term Use: Despite its general safety, concerns have been raised about chronic high intake. Such supplementation may alter the body's natural amino acid balance, impair endogenous glutamine synthesis, and potentially modulate immune function in unforeseen ways.[39] Critically, large-scale randomized trials in critically ill patients with multiorgan failure found that high-dose glutamine supplementation was associated with an increase in mortality, especially in those with renal dysfunction, leading to recommendations against its routine use in this specific population.[45]
• Contraindications and At-Risk Populations: The use of L-Glutamine supplements is contraindicated or requires significant caution in several populations. In patients with severe liver disease, the ammonia load from glutamine metabolism can exacerbate hyperammonemia and precipitate or worsen hepatic encephalopathy.[22] Caution is also advised in patients with kidney disease, Reye's syndrome, bipolar disorder (due to a potential risk of inducing mania from increased glutamate levels), and seizure disorders.[22] Individuals with a known sensitivity to monosodium glutamate (MSG) may also react to glutamine, as the body converts glutamine to glutamate.[44]

4.2 Potential Toxicological Mechanisms Specific to D-Glutamine

The toxicity of D-Glutamine is not expected to arise from the parent compound itself but from the unique products of its metabolism by DAAO.

• H2​O2​-Mediated Oxidative Stress: The most direct and significant toxicological mechanism is the generation of hydrogen peroxide (H2​O2​).[32] As a reactive oxygen species, H2​O2​ can overwhelm cellular antioxidant defenses (such as catalase and the glutathione peroxidase system), leading to oxidative damage to vital macromolecules. This mechanism is directly implicated in the nephrotoxicity observed with other DAAO substrates like D-serine, where the production of H2​O2​ in the DAAO-rich proximal tubules causes renal damage.[32] Any therapeutic or toxic effect of D-Glutamine would be intrinsically linked to the balance between its rate of H2​O2​ production and the capacity of the target tissue to neutralize it.
• Ammonia (NH4+​) Toxicity: Similar to L-Glutamine, the metabolism of D-Glutamine releases ammonia. This places a metabolic burden on the liver to detoxify it via the urea cycle. In individuals with normal hepatic function, this is unlikely to be an issue at moderate doses. However, in patients with hepatic impairment, the administration of D-Glutamine could lead to a dangerous accumulation of ammonia in the blood, with potentially severe neurological consequences.[12]
• Glutamate-Mediated Excitotoxicity: A theoretical concern is the potential for increased levels of the excitatory neurotransmitter glutamate. While one study in mouse brain tissue did not detect D-glutamate, the possibility remains that D-Glutamine's α-keto acid metabolite, 2-oxoglutaramate, could be transaminated to form glutamate.[26] An excess of glutamate in the central nervous system can lead to excitotoxicity, a process of neuronal damage caused by overstimulation of glutamate receptors, which is implicated in stroke, epilepsy, and neurodegenerative diseases.[37] This concern extends to interactions with medications, as there is a warning that glutamine may increase seizure risk and potentially diminish the efficacy of anticonvulsant drugs.[44]

4.3 Overall Safety Assessment and Critical Data Gaps

The most significant challenge in assessing D-Glutamine's safety is the complete absence of dedicated toxicology studies in the available literature. Its safety profile is entirely inferred. The primary unanswered questions revolve around the quantitative aspects of its metabolism in humans: what is the precise rate of H2​O2​ and ammonia production from a given oral or intravenous dose of D-Glutamine, and what is the capacity of the human kidney and liver to safely manage these toxic byproducts?

A crucial point of analysis reveals a fundamental biochemical opposition between the two glutamine enantiomers regarding cellular redox balance. L-Glutamine serves as a key precursor for the synthesis of glutathione (GSH), the body's master antioxidant. Its administration, therefore, supports an anti-oxidant state by bolstering cellular defenses against ROS.[16] In complete contrast, the metabolism of D-Glutamine via DAAO directly

produces the oxidant H2​O2​, promoting a pro-oxidant state.[33] This stark dichotomy explains the divergent therapeutic strategies being explored for the two isomers. L-Glutamine is investigated for protective roles in conditions of high oxidative stress (e.g., critical illness, post-surgery), whereas D-Glutamine's potential lies in scenarios where inducing targeted oxidative stress and cytotoxicity could be beneficial, such as in cancer therapy. They are not interchangeable; they are biochemical tools with opposing effects on a critical cellular process.

5.0 Therapeutic, Diagnostic, and Research Applications

While D-Glutamine itself has no approved therapeutic uses, its potential applications can be understood by contrasting them with the established roles of L-Glutamine and by situating D-Glutamine within the rapidly advancing field of D-amino acid research.

5.1 Established and Investigational Uses of L-Glutamine

The therapeutic value of L-Glutamine is well-established, with two FDA-approved formulations and numerous investigational uses primarily focused on supporting the body during periods of intense metabolic stress.

• FDA-Approved Indications:
• Sickle Cell Disease: Marketed as Endari®, oral L-glutamine powder was approved by the FDA in 2017 to reduce the acute complications of sickle cell disease in adult and pediatric patients aged five years and older.[34] The approval was based on a Phase 3 clinical trial that demonstrated a statistically significant reduction in the median number of pain crises and fewer hospitalizations compared to placebo.[34] The proposed mechanism of action involves L-glutamine's role in the synthesis of nicotinamide adenine dinucleotide (NAD), which improves the redox potential within sickle red blood cells, thereby reducing the oxidative damage that contributes to cell sickling and vaso-occlusion.[16]
• Short Bowel Syndrome (SBS): Marketed as NutreStore™, L-glutamine was approved in 2004 for the treatment of SBS in patients receiving specialized nutritional support. It is used in conjunction with recombinant human growth hormone to enhance structural and functional integrity of the gastrointestinal tract, thereby improving nutrient and fluid absorption.[34]
• Investigational and Supplemental Applications:
• Clinical Nutrition: L-Glutamine is a common component of nutritional supplementation for critically ill, post-surgical, or trauma patients. It is intended to support immune cell function, maintain the integrity of the gut barrier, and improve nitrogen balance, potentially reducing infection rates and hospital stays.[11] However, clinical data on mortality benefits remain mixed.[16]
• Oncology Support: It is widely investigated for its ability to mitigate the toxic side effects of cancer therapies. Studies suggest it may reduce the severity of chemotherapy-induced mucositis (inflammation of the digestive tract), peripheral neuropathy, and diarrhea.[16]
• Gastrointestinal Health: Beyond SBS, L-glutamine is explored for its potential to maintain gut barrier function, a concept often associated with "leaky gut syndrome," and has shown some benefit in reducing symptoms for patients with irritable bowel syndrome (IBS).[3]
• Athletic Performance: Despite popular use in sports nutrition, there is little robust evidence to support claims that L-glutamine supplementation enhances athletic performance, muscle gain, or power output. Some minor benefits in reducing post-exercise muscle soreness have been reported.[22]

5.2 Investigational and Research Applications of D-Glutamine

The applications of D-Glutamine are currently confined to the laboratory and are primarily investigational, leveraging its unique properties as a D-amino acid.

• Cell Culture Reagent: D-Glutamine is utilized as an essential nutrient in various cell culture media formulations. In the production of biopharmaceuticals, where cell viability and productivity are paramount, it serves as a key energy and nitrogen source for cell growth.[3]
• Biochemical Research Tool: As a specific substrate for DAAO, D-Glutamine is a valuable tool for researchers studying D-amino acid metabolism, the function and inhibition of DAAO, and the downstream effects of its metabolites.[21] For example, it has been used in vitro to investigate its protective effects against acetaldehyde-induced disruption of the intestinal barrier function in Caco-2 cell monolayers.[21]
• Context within D-Amino Acid Therapeutics: Although D-Glutamine has no direct therapeutic applications yet, its potential must be viewed within the broader, emerging field of D-amino acid-based therapies. This field is exploring several innovative strategies [25]:
• Targeted Cytotoxicity in Oncology: Using D-amino acids as prodrugs to generate cytotoxic H2​O2​ specifically in DAAO-expressing tumors.
• Neuromodulation: Utilizing D-amino acids like D-serine and D-alanine as direct modulators of NMDA receptors to treat psychiatric conditions like schizophrenia.
• Tissue Protection: Employing D-methionine to selectively protect healthy tissues from the toxic side effects of chemotherapy agents like cisplatin.
• Enhanced Drug Stability: Incorporating D-amino acids into peptide-based drugs to render them resistant to degradation by proteases, thereby increasing their in vivo half-life and efficacy.[57]

5.3 D-Glutamine as a Potential Disease Biomarker

One of the most intriguing areas of D-Glutamine research is its potential as a non-invasive biomarker for various diseases. However, the current data present a complex and sometimes contradictory picture.

• Hepatocellular Carcinoma (HCC) and Pancreatitis: Studies have reported that serum levels of D-Glutamine are significantly reduced in patients with HCC and in rat models of acute pancreatitis.[4] This suggests that these disease states may involve either increased consumption of D-Glutamine by the diseased tissue or altered host metabolism leading to its depletion.
• Colorectal Cancer (CRC): In contrast, a study analyzing urine from CRC patients found that D-Gln levels were significantly elevated in patients with Stage IV disease compared to Stage I.[56] This finding points towards D-Gln as a potential indicator of cancer progression and metastasis.
• Nonalcoholic Steatohepatitis (NASH): Research has linked disordered glutamine metabolism to the severity of liver fibrosis in NASH. The plasma glutamate/glutamine ratio increases with fibrosis severity. Furthermore, preclinical studies using the PET tracer 18F-fluoroglutamine have shown increased uptake in fibrotic livers, suggesting this could be a viable non-invasive method for diagnosing and staging NASH.[60]

The discrepancy between these findings—reduced D-Glutamine in the serum of HCC patients versus elevated levels in the urine of advanced CRC patients—is significant. It strongly suggests that systemic D-Glutamine levels are not a simple reflection of a single disease process. Instead, they likely represent a complex integration of multiple factors: the metabolic activity of the tumor itself (which may consume or release D-Glutamine), the activity of the gut microbiome (a primary source of D-amino acids), and the metabolic capacity of the host, particularly the DAAO activity in the liver and kidneys. A low serum level in HCC could reflect increased clearance by a DAAO-expressing liver tumor, while high urinary levels in CRC could reflect overproduction by an altered gut microbiome, with the excess being cleared by the kidneys. This complexity implies that to truly harness D-Glutamine as a reliable biomarker, future studies will need to move beyond single-compartment measurements and adopt a more holistic, multi-compartment approach (e.g., analyzing blood, urine, and fecal samples) in conjunction with gut microbiome profiling to disentangle these interacting variables.

6.0 Regulatory and Commercial Landscape

The regulatory and commercial status of glutamine provides a compelling case study in drug development, highlighting the differing standards of regulatory agencies and the clear distinction between a therapeutic agent and a research chemical. While L-Glutamine has navigated the complex path to approval, D-Glutamine remains firmly in the preclinical and research domain.

6.1 Regulatory Status and Approval History of L-Glutamine

The journey of L-Glutamine to market approval reveals significant differences in regulatory interpretation between major global health authorities.

6.1.1 U.S. Food and Drug Administration (FDA)

The FDA has approved L-glutamine for two distinct indications:

• NutreStore™: Approved in 2004, this formulation of L-glutamine powder for oral solution is indicated for the treatment of Short Bowel Syndrome (SBS) in patients receiving specialized nutritional support, used alongside recombinant human growth hormone.[34]
• Endari®: Approved on July 7, 2017, Endari (L-glutamine oral powder) is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.[34] The approval was based on a 48-week, randomized, placebo-controlled Phase 3 trial involving 230 patients. The trial demonstrated that patients treated with L-glutamine experienced fewer sickle cell crises (median of 3 vs. 4 for placebo), fewer hospitalizations, and a lower incidence of acute chest syndrome.[34] The application for this indication was submitted via the 505(b)(2) pathway, which allows an applicant to rely, in part, on the FDA's previous findings of safety and/or effectiveness for a previously approved product, in this case, NutreStore™.[34] This pathway streamlined the development process. Notably, the FDA's Oncologic Drugs Advisory Committee voted in favor of approval despite acknowledging significant challenges with the trial data, including large and differential patient dropout rates between the treatment and placebo arms, which required the FDA to conduct multiple sensitivity analyses to validate the results.[34]

6.1.2 European Medicines Agency (EMA)

The regulatory outcome in Europe for the same L-glutamine product for sickle cell disease was markedly different.

• Xyndari: The marketing authorisation application for Xyndari (glutamine), submitted by Emmaus Medical Europe Ltd, was withdrawn by the company on September 18, 2019.[61]
• Reason for Withdrawal: The withdrawal was not a strategic decision made in a vacuum; it occurred after the EMA's Committee for Medicinal Products for Human Use (CHMP) had completed its evaluation and recommended refusing the marketing authorisation. At the time of withdrawal, this negative opinion was under a re-examination process requested by the company.[61] The EMA's primary objection centered on the reliability and interpretation of the pivotal clinical trial. The agency expressed significant concerns about the high number of patients who dropped out of the study, particularly the differential rates between the treatment arms, and deemed the statistical methods used by the company to handle this missing data to be inappropriate. Consequently, the CHMP concluded that the benefits of Xyndari in treating sickle cell disease had not been sufficiently demonstrated by the submitted data.[61]

This divergence in regulatory outcomes for the same drug, based on the same pivotal trial, is a powerful illustration of how differing regulatory philosophies, particularly regarding the statistical handling of missing data in clinical trials, can lead to different conclusions about a drug's risk-benefit profile. The EMA's more stringent position on the impact of patient dropouts on trial integrity was the decisive factor in its negative assessment, contrasting with the FDA's decision to approve based on sensitivity analyses that supported the primary finding.

6.2 Commercial Availability of D-Glutamine

Unlike its L-isomer, D-Glutamine is not an approved therapeutic agent or dietary supplement. Its availability is restricted to the research and development sector.

• Status: D-Glutamine is commercially available as a research-grade chemical.[3]
• Suppliers: It is offered by major chemical suppliers, including Sigma-Aldrich (MilliporeSigma), Cayman Chemical, and Chemimpex.[3]
• Form and Purity: It is typically sold as a white, crystalline powder with a purity of ≥98% or higher, as confirmed by methods like HPLC.[3]
• Intended Use: Product documentation explicitly states that it is intended for laboratory research, cell culture, and biochemical applications. It is consistently marked with warnings such as "not for human or veterinary use," clearly delineating its status from the pharmaceutical-grade L-glutamine used in Endari® and NutreStore™.[35]

6.3 Overview of Relevant Patent History

The patent landscape for glutamine reflects the evolving scientific understanding and technological capabilities over several decades.

• Early Synthetic Methods: Patents dating back to the 1950s and 1960s describe novel processes for the chemical synthesis of DL-glutamine, the racemic mixture of both enantiomers. A 1960 patent, for instance, details a multi-step synthesis from glutamic acid and phthalic anhydride.[62] These early patents already recognized the potential therapeutic utility of glutamine, citing its experimental use in treating epilepsy and mental retardation, underscoring a long-standing interest in its biological effects.[62]
• Peptide Derivatives: Later patents, such as one from 1991, shifted focus to the synthesis of glutamine-containing peptides. These patents often specify the use of D-, L-, or DL-amino acids to create novel peptide derivatives. A key motivation for incorporating D-amino acids into peptide structures is to enhance their stability against degradation by proteases, a common strategy in modern peptide drug design.[63]
• Modern Genetic Engineering: More recent intellectual property reflects the shift towards biotechnology and genetic engineering. A 2015 patent application, for example, describes methods for inactivating the glutamine synthetase gene in cell lines.[64] This technology is relevant for the industrial production of recombinant proteins in cell cultures, where controlling cellular metabolism is crucial for maximizing yield and quality.

7.0 Emerging Research and Future Directions

The body of evidence on D-Glutamine, while sparse compared to its L-isomer, points towards a future where it may transition from a biochemical curiosity to a molecule of significant therapeutic and diagnostic interest. This evolution in perspective requires contextualizing D-Glutamine within major research paradigms, particularly in oncology, and as part of the broader, burgeoning field of D-amino acid therapeutics.

7.1 Contextualizing D-Glutamine within "Glutamine Addiction" in Oncology

A dominant theme in modern cancer metabolism research is the concept of "glutamine addiction." This refers to the observation that many types of cancer cells become highly dependent on a continuous supply of L-Glutamine to sustain their rapid growth and proliferation.[27] Cancer cells utilize L-Glutamine for several critical functions:

• Anaplerosis: Fueling the TCA cycle to generate energy (ATP).
• Biomass Production: Providing essential carbon and nitrogen atoms for the synthesis of nucleotides, lipids, and other non-essential amino acids.
• Redox Homeostasis: Serving as the precursor for glutathione (GSH) synthesis to combat oxidative stress.[13]

This dependency has made the L-glutamine metabolic pathway, and particularly the enzyme glutaminase (GLS), a prime therapeutic target. The strategy is straightforward: inhibit GLS to starve the cancer cells of a critical nutrient, thereby halting their growth.[65]

Within this context, D-Glutamine presents a fascinating paradox. It does not participate in the glutaminolysis pathway and therefore cannot be used by cancer cells as a nutrient in the same way as L-Glutamine. Instead, its metabolism via D-amino acid oxidase (DAAO) directly produces the cytotoxic oxidant H2​O2​.[33] This completely inverts the therapeutic strategy. Instead of inhibiting a metabolic pathway to induce starvation, D-Glutamine offers the potential for a substrate-driven therapy that actively generates a toxic byproduct. The hypothesis is that administering D-Glutamine to a patient whose tumor expresses DAAO could lead to the targeted, intracellular production of

H2​O2​, inducing oxidative stress and selectively killing the cancer cells. This approach transforms D-Glutamine from a non-nutrient into a potential prodrug for targeted cancer therapy.

7.2 The Broader Therapeutic Potential of D-Amino Acids: A New Frontier

The potential of D-Glutamine should not be considered in isolation but as part of the expanding therapeutic landscape of D-amino acids. Once dismissed as biologically irrelevant in mammals, D-amino acids are now recognized as having unique physiological roles and significant therapeutic potential.[25] Key research avenues include:

• Prodrugs for Targeted Therapy: As hypothesized for D-Glutamine, other D-amino acids can act as prodrugs to deliver a cytotoxic payload (H2​O2​) specifically to DAAO-expressing tissues, such as tumors.[56]
• Neuromodulation: D-Serine and D-Alanine are now understood to be endogenous co-agonists of the NMDA receptor in the brain. Modulating their levels, for instance by inhibiting their degradation by DAAO, is a major therapeutic strategy being investigated for the cognitive and negative symptoms of schizophrenia and other CNS disorders.[25]
• Selective Tissue Protection: D-Methionine has shown a remarkable ability to protect healthy tissues, particularly the kidneys and inner ear, from the toxic side effects of cisplatin chemotherapy without compromising the drug's anti-tumor efficacy.[25]
• Anti-Infective Agents: Mixtures of D-amino acids have been found to effectively disperse and prevent the formation of bacterial biofilms, which are a major cause of chronic and antibiotic-resistant infections. This could enhance the efficacy of conventional antibiotics.[25]
• Improving Peptide Drug Properties: The incorporation of D-amino acids into therapeutic peptides is a well-established strategy to increase their stability against degradation by proteases. This modification can significantly extend the in vivo half-life and improve the pharmacokinetic profile of peptide-based drugs.[57]

7.3 In-depth Analysis and Recommendations for Future Research

The synthesis of the available data reveals several critical knowledge gaps and points towards a clear roadmap for future D-Glutamine research. To unlock its potential, the scientific community must address the following fundamental questions:

1. Comprehensive Pharmacokinetic Characterization: The most immediate need is to conduct formal ADME (Absorption, Distribution, Metabolism, Excretion) studies. Preclinical studies in animal models are required to determine the oral bioavailability, plasma half-life, volume of distribution, and the quantitative contribution of the two main clearance pathways: DAAO-mediated metabolism versus direct renal excretion. This is a prerequisite for any rational dose selection in future human trials.
2. Systematic Mapping of DAAO Expression in Disease: The therapeutic potential of D-Glutamine is entirely conditional on the expression of DAAO in target tissues. A systematic effort is needed to profile DAAO protein expression and enzymatic activity across a wide spectrum of human pathologies, especially diverse cancer types. Techniques like immunohistochemistry on tumor microarrays and activity assays on tissue homogenates would identify which diseases are the most promising candidates for a D-Glutamine-based therapeutic strategy.
3. Validation of the D-Glutamine Cytotoxicity Hypothesis: The central therapeutic hypothesis—that D-Glutamine can selectively kill DAAO-expressing cancer cells—must be rigorously tested. This involves in vitro studies on cancer cell lines with varying levels of DAAO expression, correlating D-Glutamine-induced cell death with DAAO levels and the production of H2​O2​. Positive in vitro results must then be validated in corresponding in vivo xenograft models to demonstrate anti-tumor efficacy and assess safety in a whole-organism context.
4. Elucidation of the Biomarker Discrepancy: The conflicting reports on D-Glutamine as a biomarker (decreased in HCC serum, increased in CRC urine) must be resolved. This requires a more sophisticated, multi-compartment metabolomics approach. Future studies should simultaneously measure D-Glutamine levels in plasma, urine, and fecal samples from patients, and correlate these levels with gut microbiome composition (via 16S or shotgun sequencing) and tumor DAAO expression. This will help to disentangle the relative contributions of host metabolism, tumor metabolism, and microbial production to the systemic D-Glutamine pool.
5. Investigation of Potential Neurological Roles: The detection of endogenous D-Glutamine in the brain, coupled with the central role of the L-glutamate/L-glutamine cycle in neurotransmission, raises the question of whether D-Glutamine has a specific function in the CNS.[18] Research should explore whether D-Glutamine can modulate neuronal signaling, either directly or indirectly through its metabolism by DAAO in astrocytes, or if its presence is merely a metabolic curiosity.

Ultimately, the entire body of evidence points toward a significant paradigm shift. D-Glutamine should no longer be viewed as a simple, "unimportant" isomer of L-Glutamine. Its value lies precisely in its orthogonal metabolism. The logical path forward for its development as a therapeutic agent is not as a standalone drug, but as part of a precision medicine strategy. The future of D-Glutamine therapy is inextricably linked to the development of DAAO as a companion diagnostic. A drug-diagnostic co-development approach, where a DAAO test (e.g., an immunohistochemical assay or a DAAO-specific PET imaging agent) is used to select patients whose tumors express the target enzyme, would be the most rational and effective way to translate the unique biochemistry of D-Glutamine into a viable clinical tool. This approach would embody the principles of modern, targeted therapy, potentially unlocking a novel treatment modality for a specific subset of cancers and other diseases.

8.0 References

[1]

Works cited

1. D-Glutamine: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed August 6, 2025, https://go.drugbank.com/drugs/DB02174
2. D-Glutamine | C5H10N2O3 | CID 145815 - PubChem, accessed August 6, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/D-Glutamine
3. D-Glutamine - Chem-Impex, accessed August 6, 2025, https://www.chemimpex.com/products/00156
4. D-Glutamine (D-Gln, CAS Number: 5959-95-5) | Cayman Chemical, accessed August 6, 2025, https://www.caymanchem.com/product/27032/d-glutamine
5. D-Glutamine (ECMDB03423) (M2MDB000500) - ECMDB, accessed August 6, 2025, https://ecmdb.ca/compounds/M2MDB000500
6. Ligand DGN bound in PDB entry 7ll9 ‹ Protein Data Bank in Europe, accessed August 6, 2025, https://www.ebi.ac.uk/pdbe/entry/pdb/7ll9/bound/DGN
7. D-Glutamine | CAS 5959-95-5 | TCI-G0278 | Spectrum Chemical, accessed August 6, 2025, https://www.spectrumchemical.com/d-glutamine-tci-g0278
8. MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated) (DB02174) | DrugBank Online, accessed August 6, 2025, https://go.drugbank.com/spectra/ms_ms/2302
9. Glutamine: Metabolism and Immune Function, Supplementation and ..., accessed August 6, 2025, https://www.mdpi.com/2072-6643/10/11/1564
10. Glutamine - Wikipedia, accessed August 6, 2025, https://en.wikipedia.org/wiki/Glutamine
11. Glutamine: What It Is, Benefits & Side Effects - Cleveland Clinic, accessed August 6, 2025, https://my.clevelandclinic.org/health/articles/glutamine
12. Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation - PMC - PubMed Central, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6266414/
13. Glutamine Metabolism - Cell Signaling Technology, accessed August 6, 2025, https://www.cellsignal.com/pathways/glutamine-metabolism
14. Glutamine Metabolism Pathway - Boster Bio, accessed August 6, 2025, https://www.bosterbio.com/pathway-maps/cellular-metabolism/glutamine-metabolism
15. Glutamine - Military Strategies for Sustainment of Nutrition and Immune Function in the Field, accessed August 6, 2025, https://www.ncbi.nlm.nih.gov/books/NBK230973/
16. Glutamine - Memorial Sloan Kettering Cancer Center, accessed August 6, 2025, https://www.mskcc.org/cancer-care/integrative-medicine/herbs/glutamine
17. L-Glutamine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 6, 2025, https://go.drugbank.com/drugs/DB00130
18. The role of glutamate and glutamine metabolism and related transporters in nerve cells, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10867874/
19. www.healthline.com, accessed August 6, 2025, https://www.healthline.com/nutrition/glutamine#:~:text=While%20L%2Dglutamine%20is%20used,fluids%20(%205%20%2C%206%20).
20. Glutamine: Benefits, Uses and Side Effects - Healthline, accessed August 6, 2025, https://www.healthline.com/nutrition/glutamine
21. D -Glutamine = 98 HPLC 5959-95-5 - Sigma-Aldrich, accessed August 6, 2025, https://www.sigmaaldrich.com/AN/en/product/sigma/g9003
22. Glutamine: Health Benefits, Safety Information, Dosage, and More - WebMD, accessed August 6, 2025, https://www.webmd.com/diet/health-benefits-glutamine
23. D-Amino acid metabolism in bacteria | The Journal of Biochemistry - Oxford Academic, accessed August 6, 2025, https://academic.oup.com/jb/article/170/1/5/6206782
24. Amino acids as the source of ammonium ions - UCL, accessed August 6, 2025, https://www.ucl.ac.uk/~ucbcdab/urea/sources.htm
25. Promising Application of D-Amino Acids toward Clinical Therapy, accessed August 6, 2025, https://www.mdpi.com/1422-0067/23/18/10794
26. D-Amino Acid Levels in Perfused Mouse Brain Tissue and Blood: A Comparative Study, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5479723/
27. Glutamine Metabolism: Molecular Regulation, Biological Functions, and Diseases - PMC, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12188105/
28. Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer - Frontiers, accessed August 6, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1143798/full
29. Glutamine and glutamate as vital metabolites - SciELO, accessed August 6, 2025, https://www.scielo.br/j/bjmbr/a/HnKLvvJXLwTXg8WfCKx3Xvn/
30. Human D-Amino Acid Oxidase: Structure, Function, and Regulation ..., accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6279847/
31. D-amino acid oxidase - Wikipedia, accessed August 6, 2025, https://en.wikipedia.org/wiki/D-amino_acid_oxidase
32. Human D-Amino Acid Oxidase: Structure, Function, and Regulation - Frontiers, accessed August 6, 2025, https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2018.00107/full
33. D-amino-acid oxidase - Talaromyces emersonii (Thermophilic fungus) | UniProtKB | UniProt, accessed August 6, 2025, https://www.uniprot.org/uniprotkb/A0A499UB99/entry
34. FDA D.I.S.C.O.: L-glutamine for sickle cell disease | FDA, accessed August 6, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-l-glutamine-sickle-cell-disease
35. Cayman D-Glutamine; Purity- Greater Than Or Equal To 95%; Size- 1 - Neta Scientific, accessed August 6, 2025, https://www.netascientific.com/biochemical-reagents/caym-27032-1
36. Biochemical Properties of Human D-Amino Acid Oxidase - PMC, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5737116/
37. Disturbance of the Glutamate-Glutamine Cycle, Secondary to Hepatic Damage, Compromises Memory Function - Frontiers, accessed August 6, 2025, https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2021.578922/full
38. Assessment of the safety of glutamine and other amino acids - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/11533313/
39. Side effects of long-term glutamine supplementation - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/22990615/
40. Glutamine (oral route) - Side effects & dosage - Mayo Clinic, accessed August 6, 2025, https://www.mayoclinic.org/drugs-supplements/glutamine-oral-route/description/drg-20064099
41. The Therapeutic Potential of D-Amino Acid Oxidase (DAAO) Inhibitors - PubMed Central, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2905773/
42. C:\Documents and Settings\CLAYTONT\My Documents\N21667 ..., accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21677_nutreStore_lbl.pdf
43. Role of renal d -amino-acid oxidase in pharmacokinetics of d -leucine, accessed August 6, 2025, https://www.periodicos.capes.gov.br/index.php/acervo/buscador.html?task=detalhes&id=W2135997515
44. GLUTAMINE: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews, accessed August 6, 2025, https://www.webmd.com/vitamins/ai/ingredientmono-878/glutamine
45. What are the adverse effects of glutamine? - Consensus, accessed August 6, 2025, https://consensus.app/search/what-are-the-adverse-effects-of-glutamine/aAcU9brvQ2aIbG7jc97wYw/
46. Excitotoxicity - Wikipedia, accessed August 6, 2025, https://en.wikipedia.org/wiki/Excitotoxicity
47. Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment - Frontiers, accessed August 6, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1345522/full
48. Endari (L-glutamine) FDA Approval History - Drugs.com, accessed August 6, 2025, https://www.drugs.com/history/endari.html
49. Systematic Review of l-glutamine for Prevention of Vaso-occlusive Pain Crisis in Patients with Sickle Cell Disease - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/31505045/
50. pmc.ncbi.nlm.nih.gov, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6266414/#:~:text=Currently%2C%20glutamine%20is%20routinely%20supplied,athletes%20to%20restore%20immune%20functions.
51. Leaky Gut Syndrome: Symptoms, Diet, Tests & Treatment - Cleveland Clinic, accessed August 6, 2025, https://my.clevelandclinic.org/health/diseases/22724-leaky-gut-syndrome
52. Glutamine benefits, dosage, and side effects - Examine.com, accessed August 6, 2025, https://examine.com/supplements/glutamine/
53. D -Glutamine = 98 HPLC 5959-95-5 - Sigma-Aldrich, accessed August 6, 2025, https://www.sigmaaldrich.com/FO/en/product/sigma/g9003
54. D -Glutamine = 98 HPLC 5959-95-5 - Sigma-Aldrich, accessed August 6, 2025, https://www.sigmaaldrich.com/SL/en/product/sigma/g9003
55. D -Glutamine = 98 HPLC 5959-95-5 - Sigma-Aldrich, accessed August 6, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/g9003
56. Biological and Analytical Perspectives on D-Amino Acids in Cancer ..., accessed August 6, 2025, https://www.mdpi.com/1424-8247/18/5/705
57. Promising Application of D-Amino Acids toward Clinical Therapy - ResearchGate, accessed August 6, 2025, https://www.researchgate.net/publication/363619239_Promising_Application_of_D-Amino_Acids_toward_Clinical_Therapy
58. Promising Application of D-Amino Acids toward Clinical Therapy - PMC - PubMed Central, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9503604/
59. d-Amino Acid-Based Protein Arginine Deiminase Inhibitors: Synthesis, Pharmacokinetics, and in Cellulo Efficacy | ACS Medicinal Chemistry Letters - ACS Publications, accessed August 6, 2025, https://pubs.acs.org/doi/10.1021/ml300288d
60. Glutamine Breakdown as a Potential Metabolic Biomarker for Nonalcoholic Steatohepatitis, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7296225/
61. Xyndari | European Medicines Agency (EMA), accessed August 6, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/xyndari
62. US2951090A - Preparation of dl-glutamine - Google Patents, accessed August 6, 2025, https://patents.google.com/patent/US2951090A/en
63. US5032675A - Process for the production of glutamine derivatives - Google Patents, accessed August 6, 2025, https://patents.google.com/patent/US5032675A/en
64. methods and compositions for inactivating glutamine synthetase gene expression, accessed August 6, 2025, https://patents.justia.com/patent/20150087067
65. Advancing Cancer Treatment by Targeting Glutamine Metabolism—A Roadmap - MDPI, accessed August 6, 2025, https://www.mdpi.com/2072-6694/14/3/553
66. Targeting glutamine metabolism as a potential target for cancer treatment - PMC, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12210561/
67. Glutamine's double-edged sword: fueling tumor growth and offering therapeutic hope - Frontiers, accessed August 6, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1578940/full
68. L-Glutamine-d5 (L-Glutamic acid 5-amide-d5) | Stable Isotope - MedchemExpress.com, accessed August 6, 2025, https://www.medchemexpress.com/l-glutamine-d5.html
69. l-Glutamine for sickle cell anemia: more questions than answers | Blood, accessed August 6, 2025, https://ashpublications.org/blood/article-abstract/132/7/689/39431
70. L-Glutamine | C5H10N2O3 | CID 5961 - PubChem, accessed August 6, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/L-Glutamine
71. Semaglutide - Wikipedia, accessed August 6, 2025, https://en.wikipedia.org/wiki/Semaglutide
72. Pheburane | European Medicines Agency (EMA), accessed August 6, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/pheburane
73. Monosodium glutamate - Wikipedia, accessed August 6, 2025, https://en.wikipedia.org/wiki/Monosodium_glutamate
74. Glutamine is critical for the maintenance of type 1 conventional dendritic cells in normal tissue and the tumor microenvironment | PNAS, accessed August 6, 2025, https://www.pnas.org/doi/10.1073/pnas.2412157121
75. Pyroglutamic acid - Wikipedia, accessed August 6, 2025, https://en.wikipedia.org/wiki/Pyroglutamic_acid
76. Amino Acid Oxidase, D- | Worthington Biochemical, accessed August 6, 2025, https://www.worthington-biochem.com/products/amino-acid-oxidase-d
77. Glutamine and Cancer: How It Works, What to Do - Healthline, accessed August 6, 2025, https://www.healthline.com/health/glutamine-and-cancer
78. Mucoadhesive Andrographolide-Loaded Liposomes for Nasal Delivery Modulate Inflammatory Responses in Tumor Necrosis Factor Alpha- - ACS Publications, accessed August 6, 2025, https://pubs.acs.org/doi/pdf/10.1021/acsomega.5c03543
79. Tumor metabolome - Wikipedia, accessed August 6, 2025, https://en.wikipedia.org/wiki/Tumor_metabolome
80. Advancing Neonatal Screening for Pyridoxine-Dependent Epilepsy-ALDH7A1 Through Combined Analysis of 2-OPP, 6-Oxo-Pipecolate and Pipecolate in a Butylated FIA-MS/MS Workflow - MDPI, accessed August 6, 2025, https://www.mdpi.com/2409-515X/11/3/59
81. What is the Difference Between L-glutamine vs Glutamine? - FitBudd, accessed August 6, 2025, https://www.fitbudd.com/post/what-is-the-difference-between-l-glutamine-vs-glutamine
82. Capturing a glycosylase reaction intermediate in DNA repair by freeze-trapping of a pH-responsive hOGG1 mutant | Nucleic Acids Research | Oxford Academic, accessed August 6, 2025, https://academic.oup.com/nar/article/doi/10.1093/nar/gkaf718/8220635
83. High-Fructose-Induced Salt-Sensitive Hypertension: The Potential Benefit of SGLT4 or SGLT5 Modulation - MDPI, accessed August 6, 2025, https://www.mdpi.com/2072-6643/17/15/2511
84. Safety and metabolic effects of L-glutamine administration in humans - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/2119459/
85. Thirteen-Week Oral Toxicity Study of L-Glutamine in Rats | Request PDF - ResearchGate, accessed August 6, 2025, https://www.researchgate.net/publication/292138388_Thirteen-Week_Oral_Toxicity_Study_of_L-Glutamine_in_Rats
86. The Role of Glutamine Homeostasis in Emotional and Cognitive Functions - MDPI, accessed August 6, 2025, https://www.mdpi.com/1422-0067/25/2/1302
87. Glutamine in the central nervous system: function and dysfunction - IMR Press, accessed August 6, 2025, https://article.imrpress.com/bri/Landmark/articles/pdf/Landmark2067.pdf
88. Circulating glutamine and Alzheimer's disease - Video abstract [ID 239350] - YouTube, accessed August 6, 2025, https://www.youtube.com/watch?v=nvEXdk_hzgc
89. Glutamine prevents acute kidney injury by modulating oxidative stress and apoptosis in tubular epithelial cells - PubMed Central, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9675453/
90. Glutamine Metabolism Promotes Renal Fibrosis through Regulation of Mitochondrial Energy Generation and Mitochondrial Fission - PMC, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10797689/
91. Renal Disease – Renal Failure Therapies - Consult Dr. Anderson, accessed August 6, 2025, https://www.consultdranderson.com/renal-disease-renal-failure-therapies/
92. Glutamine levels predict renal failure in patients treated with cisplatinum - Nefrología, accessed August 6, 2025, https://www.revistanefrologia.com/index.php?p=revista&tipo=pdf-simple&pii=X2013251407020776
93. Glutamine and Kidney Function - Effect on Nitrogen Balance - Consult Dr. Anderson, accessed August 6, 2025, https://www.consultdranderson.com/glutamine-and-kidney-function-effect-on-nitrogen-balance/
94. The Preventive Role of Glutamine Supplementation in Cardiac Surgery-Associated Kidney Injury from Experimental Research to Clinical Practice: A Narrative Review - MDPI, accessed August 6, 2025, https://www.mdpi.com/1648-9144/60/5/761
95. Glutamine - Sigma-Aldrich, accessed August 6, 2025, https://www.sigmaaldrich.com/US/en/search/glutamine?focus=products&page=1&perpage=30&sort=relevance&term=glutamine&type=product